|Bid||0.00 x 1000|
|Ask||0.00 x 800|
|Day's Range||63.64 - 68.63|
|52 Week Range||56.34 - 138.52|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 14, 2022 - Mar 18, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||122.89|
Pfizer (PFE), Beam Therapeutics, AbbVie, Merck and Glaxo are highlighted in this analyst blog article.
Beam Therapeutics (NASDAQ: BEAM) recently signed a major research deal with Pfizer (NYSE: PFE) that could be worth up to $1.35 billion, and hardly anyone seemed to notice. Instead of surging higher in response to the Pfizer deal, Beam Therapeutics stock actually fell nearly 2% on the day of the announcement. Over the past few years, Pfizer has watched its peers experiment with CRISPR-based gene editing techniques without making any significant investments.
After 35% plunge in 2021, the gambling stock looks attractive. Also, Wall Street opinions on Domino’s Pizza, Tower Semiconductor, Beam Therapeutics, and Kratos Defense & Security Solutions.